BioWorld

March 15, 2004

Stock Winners and Losers For The Week

Clinical Trials Update: February 2004

Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: February 2004

FDA Submissions, Approvals And Other Actions: February 2004

BioWorld Stock Report For Public Biotechnology Companies

Spinal Arthritis Market Worthwhile As 'Add-On' To Existing Therapies

Industry pundits have been chanting about "consolidation" for years, using each new buyout as a way of proving their forecast - which, let's face it, is pretty much a fail-safe prediction. Read More

Money Raised Year To Date

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...